natgillin/translations-raw huggingface dataset:
Overall, the number of applications is stable, with 112 applications for marketing authorisations for medicines for human use and 13 for veterinary use forecast.
Na splošno se število vlog ne spreminja, kar pomeni predvidoma 112 vlog za izdajo dovoljenja za promet z zdravili za uporabo v humani industriji in 13 za zdravila za uporabo v veterinarski industriji.
The meeting noted a detailed update about progress on the implementation of provisions foreseen in the new pharmacovigilance legislation.
Udeleženci seje so se seznanili z najnovejšimi podrobnimi podatki o napredku pri izvajanju določb iz nove zakonodaje o farmakovigilanci.
• Written procedure for adoption of non-automatic carry-over of appropriations from 2011-2012 closed on 30 January 2012.
• Pisni postopek za sprejetje nesamodejnega prenosa odobrenih proračunskih sredstev iz leta 2011 v leto 2012, končan 30. januarja 2012.
Due to travel arrangements, some members are obliged to leave before the meeting finishes.
Nekateri člani morajo sejo zaradi potovanja zapustiti pred koncem.
• Presentation on public hearings in Europe.
• Predstavitev o javnih obravnavah v Evropi.
The underlying principle is to allow enough time for the CHMP/CMD(h) to review and debate the outcomes of the PRAC meetings.
Temeljno načelo je, naj se odboru CHMP/skupini CMD(h) omogoči dovolj časa za pregled in razpravo o ugotovitvah sej odbora PRAC.
e.) Second update on implementation of the conflicts of interests policy for staff
e) Druga posodobitev informacij o izvajanju politike o navzkrižjih interesov za osebje
The challenges in this approach are that there may be increased pressure from external parties on the CHMP/CMD(h) and that Member States may act prior to CHMP/CMD(h) outcomes.
Težavi pri tem pristopu sta morebitni večji pritisk zunanjih strani na odbor CHMP/skupino CMD(h) in morebitno ukrepanje držav članic pred ugotovitvami odbora CHMP/skupine CMD(h).
The PRAC is an independent committee and, moreover, considering that the rapporteurships in the initial evaluation stage are not evenly spread out among the Member States, the Commission took the view that the PRAC rapporteur should be from a different Member State than the rapporteur in the pre-authorisation phase.
Komisija je glede na to, da je PRAC neodvisen odbor, in ob upoštevanju, da poročanje v prvi fazi ocenjevanja ni enakomerno razporejeno med države članice, menila, da mora biti poročevalec odbora PRAC iz druge države članice kot poročevalec v fazi pred izdajo dovoljenja za promet.
Work programme and preliminary draft budget 2013
Delovni program in predhodni predlog proračuna za leto 2013
The Board agreed on a process to prepare for the procedure.
Upravni odbor se je dogovoril tudi glede priprave za postopek.
Organisation of Management Board meetings
Organiziranje sej upravnega odbora
[EMA/112052/2012] The Management Board noted the report on a sample of key performance indicators included in contractual arrangements with national competent authorities.
(EMA/112052/2012) Upravni odbor se je seznanil s poročilom o vzorcu ključnih kazalnikov uspešnosti, vključenih v pogodbene dogovore s pristojnimi nacionalnimi organi.
Rapporteurship arrangements could be reviewed after that time.
Tedaj pa se bodo lahko pregledale ureditve glede poročanja.
It was proposed that agendas and minutes of the PRAC meetings be published, initially, with those of the CHMP and CMD(h) being published in a second phase, once sufficient experience has been gathered.
Predlagano je bilo, naj se najprej objavijo dnevni redi in zapisniki sej odbora PRAC, dnevni redi in zapisniki odbora CHMP in skupine CMD(h) pa naj se objavijo v drugi fazi, po pridobitvi zadostnih izkušenj.
Pat O'Mahony participated on Thursday, 22 March 2012
Pat O'Mahony se je seje udeležil v četrtek, 22. marca 2012.
The Management Board requested details of which ICT projects will be taken forward in 2013 to be provided for the next meeting.
Upravni odbor je naročil, naj se za naslednjo sejo pripravijo podatki o tem, kateri projekti IKT se bodo nadaljevali leta 2013.
The report reveals that, despite a challenging environment, the Agency was able to deliver a growing volume of core business in 2011.
Iz poročila je razvidno,da je agencija leta 2011 kljub neugodnim okoliščinam opravila večji obseg glavnih dejavnosti.
• Presentation on implementation of the pharmacovigilance legislation.
• Predstavitev o izvajanju zakonodaje o farmakovigilanci.
[EMA/MB/139702/2012] The Management Board adopted the procedure for consultation on final composition of the Pharmacovigilance Risk Assessment Committee (PRAC).
(EMA/MB/139702/2012) Upravni odbor je sprejel postopek za posvetovanje o končni sestavi Odbora za ocenjevanje tveganja na področju farmakovigilance (PRAC).
Committee on Herbal Medicinal Products (HMPC) in June to discuss topics relating to herbal medicines.
Upravni odbor se bo junija sestal s predsednikom Odbora za zdravila rastlinskega izvora (HMPC) in se z njim pogovoril o temah, povezanih z zdravili rastlinskega izvora.
• introduction of restrictions in case of a pharmaceutical company giving a grant or other funding;
• uvedbo omejitev, če farmacevtska družba zagotovi donacijo ali drugo obliko financiranja;
• Presentation on overview of PRAC expertise so far.
• Predstavitev o pregledu dotedanjega strokovnega znanja odbora PRAC.
[EMA/MB/13210/2012] The Management Board adopted the amended rules, adjusting the fees payable to the Agency by 3.1%, for inflation.
(EMA/MB/13210/2012) Upravni odbor je sprejel spremenjena pravila in zaradi inflacije za 3,1 % zvišal pristojbine, ki se plačajo agenciji.
Its members are Klaus Cichutek, Kristin Raudsepp and Grzegorz Cessak.
Njeni člani so Klaus Cichutek, Kristin Raudsepp in Grzegorz Cessak.
Salvatore D'acunto participated on Thursday, 22 March 2012
Salvatore D'acunto se je seje udeležil v četrtek, 22. marca 2012.
[MB/EMA/155755/2012] The Management Board adopted the change to the entry grade from AST 3 to AD 6 for the post of Section Head for Financial Support services.
(MB/EMA/155755/2012) Upravni odbor je sprejel spremembo vstopnega razreda iz AST 3 v AD 6 za delovno mesto vodje oddelka za storitve finančne podpore.
The members of the group are: Marcus Müllner, Luca Pani, Kristin Raudsepp, Andrzej Rys, Gro Wesenberg and Kent Woods.
Člani skupine so: Marcus Müllner, Luca Pani, Kristin Raudsepp, Andrzej Rys, Gro Wesenberg in Kent Woods.
There was a 10% increase in the number of applications for initial-marketing authorisation for medicines for human use, with 100 applications received in 2011.
Število vlog za izdajo prvega dovoljenja za promet z zdravili za uporabo v humani medicini se je povečalo za 10 % in je obsegalo 100 prejetih vlog leta 2011.
Initiatives to set up the system for the review of raw clinical-trial data will be undertaken.
Sprejete bodo pobude za vzpostavitev sistema za pregled neobdelanih podatkov o kliničnih preizkusih.
Other members and alternates wishing to participate in these groups were invited to do so.
K sodelovanju so bili povabljeni tudi drugi člani in namestniki, ki si to želijo.
The legislation states that the Agency shall make public agendas and minutes of the Committee for Medicinal Products for Human Use (CHMP), the PRAC and the Coordination Group (CMD(h)) as regards pharmacovigilance activities, and the Board heard an update on preparations for the implementation of these provisions.
Zakonodaja določa, da agencija objavi dnevne rede in zapisnike Odbora za zdravila za uporabo v humani medicini (Committee for Medicinal Products for Human Use, CHMP), odbora PRAC in skupine za usklajevanje postopka medsebojnega priznavanja in decentraliziranega postopka v humani medicini (CoOrdination Group for Mutual Recognition and Decentralised Procedures - Human, CMD(h)) v zvezi z dejavnostmi na področju farmakovigilance, upravni odbor pa je bil seznanjen z najnovejšimi informacijami v zvezi s pripravami na izvajanje teh določb.
The budget for 2013 is €239.1 million (2012: € 222.5 million), of which the forecast fee revenue is €181.9 million.
222,5 milijona EUR) in vključuje predvideni prihodek od pristojbin v višini 181,9 milijona EUR.
List of participants at the 75th meeting of the Management Board, held in London, 21-22 March 2012
Seznam udeležencev 75. seje upravnega odbora v Londonu 21. in 22. marca 2012
Publication of agendas and minutes
Objava dnevnih redov in zapisnikov
Ways to ensure efficient and timely communication between the Agency and the European Commission, and the need for adequate financing of legislative initiatives, were among the topics discussed during the visit.
Med temami, ki so se obravnavale med obiskom, so bili načini za zagotovitev učinkovite in pravočasne komunikacije med agencijo in Evropsko komisijo ter potreba po ustreznem financiranju zakonodajnih pobud.
• EMA/MB/157253/2012 Performance of the Agency's scientific procedures: Survey 2011 for medicinal products for human use.
• EMA/157253/2012 Izsledki znanstvenih postopkov agencije: raziskava leta 2011 za zdravila za uporabo v humani medicini;
The analysis also proposed the establishment of a breach of trust procedure and a system of ex-post checks of information provided in declarations of interests (DoIs).
Na podlagi analize je bila predlagana tudi vzpostavitev postopka pri zlorabi zaupanja in sistema naknadnih preverjanj informacij iz izjav o interesih.
[EMA/MB/977044/2011] The Management Board adopted the Agency's annual report 2011.
(EMA/MB/977044/2011) Upravni odbor je sprejel letno poročilo agencije za leto 2011.
• The appointment by the Commission of six experts and patients' and healthcare professionals' representatives for the Pharmacovigilance Risk Assessment Committee (to be finalised in Q2
• imenovanjem šestih strokovnjakov ter predstavnikov bolnikov in zdravstvenih delavcev po izboru Komisije v Odbor za ocenjevanje tveganja na področju farmakovigilance (predvidoma končano v drugem četrtletju leta 2012);
[EMA/MB/146762/2012] The Management Board noted the nominations to the PRAC provided by Member States to date.
(EMA/MB/146762/2012) Upravni odbor se je seznanil z imenovanji v odbor PRAC, ki so jih do tedaj predložile države članice.
• The endorsement of the reflection paper on ethical and GCP aspects of clinical trials in third countries.
• potrditvijo študije o etičnem vidiku in vidiku dobre klinične prakse glede kliničnih preizkušanj v tretjih državah;
• Presentation on public hearings.
• Predstavitev o javnih obravnavah.
• [EMA/MB/2671/2012] Outcome of written procedures during the period 25 November 2010 to 29 February 2012.
• (EMA/MB/2671/2012) Rezultat pisnih postopkov v obdobju od 25. novembra 2010 do 29. februarja 2012;
Language regime of the Management Board meetings
Jezikovna ureditev sej upravnega odbora
• [EMA/888135/2011] MBTC-2012-02-002 Management Board Telematics Committee meeting held on 9 November 2011
• (EMA/888135/2011) MBTC-2012-02-002 Zapisnik seje odbora za telematiko pri upravnem odboru z dne 9. novembra 2011.
The decision takes affect on 22 March 2012.
Sklep začne veljati 22. marca 2012.
• EMA/135587/2012 Annual report 2011 of the Agency's Internal Audit.
• EMA/135587/2012 Letno poročilo za leto 2011 o notranji reviziji agencije;
The change reflects the increased responsibilities - staff management, authorising and reporting officers - attached to the post.
Sprememba upošteva večje odgovornosti, povezane z delovnim mestom: upravljanje osebja, ocenjevalcev in odredbodajalcev.
• EMA/135591/2012 Annual report 2011 of the Agency's Audit Advisory Committee.
• EMA/135591/2012 Letno poročilo za leto 2011 revizijskega svetovalnega odbora agencije;
d.) Revised Management Board conflicts of interests policy
d) Spremenjena politika upravnega odbora o navzkrižjih interesov
[EMA/MB/33634/2012] The Management Board noted the final minutes, adopted by written procedure on 9 February 2012.
(EMA/MB/33634/2012) Upravni odbor se je seznanil s končnim zapisnikom, ki je bil sprejet s pisnim postopkom 9. februarja 2012.
• [EMA/185199/2012] EU telematics projects report; [EMA/189200/2012] EU telematics operations report; [EMA/177625/2012] Minutes from the Management Board Telematics Committee meeting held on 14 February 2012.
• (EMA/185199/2012) Poročilo o telematskih projektih EU; (EMA/189200/2012) Poročilo o delovanju na področju telematike v EU; (EMA/177625/2012) Zapisnik seje odbora za telematiko pri upravnem odboru z dne 14. februarja 2012;
[EMA/MB/64234/2012] The Management Board adopted the revised policy on managing conflicts of interests of its members.
(EMA/MB/64234/2012) Upravni odbor je sprejel spremenjeno politiko o obvladovanju navzkrižij interesov svojih članov.
b.) Revised conflicts of interests policy for experts
b) Spremenjena politika o navzkrižjih interesov za strokovnjake
Minutes of the 75th meeting of the Management Board
Zapisnik 75. seje upravnega odbora
[EMA/MB/82882/2012] The Management Board noted the document outlining the preliminary budget for ICT project development and systems maintenance in 2013.
(EMA/MB/82882/2012) Upravni odbor se je seznanil z dokumentom, ki vključuje predhodni predlog proračuna za razvoj projektov IKT in vzdrževanje sistemov leta 2013.
• [EMA/MB/137391/2012] Overview of implementing rules to Staff Regulations signed by the MB Chair during the period from 7 October 2011 to 29 February 2012.
• (EMA/MB/137391/2012) Pregled izvedbenih pravil za kadrovske predpise, ki ga je podpisal predsednik upravnega odbora, v obdobju od 7. oktobra 2011 do 29. februarja 2012.
Patient representatives requested a possibility for both a member and an alternate to attend all PRAC meetings.
Zaprosili so za možnost, da se vseh sej odbora PRAC lahko udeležita član in namestnik.
a.) Preliminary draft work programme 2013
a) Predhodni osnutek delovnega programa za leto 2013
Another proposal offered, which would allow knowledge about a product that had been gathered at the pre-authorisation stage to be retained, was to appoint the PRAC rapporteur from among the experts who had acted as peer-reviewers in the pre-authorisation phase.
Skladno z drugim podanim predlogom, ki bi omogočil ohranitev znanja o zdravilu, pridobljenega v fazi pred izdajo dovoljenja za promet, naj se poročevalca odbora PRAC imenuje izmed strokovnjakov, ki so delovali kot strokovni ocenjevalci v fazi pred izdajo dovoljenja za promet.
It was suggested that for already authorised products and ongoing procedures, the system of the rapporteur in the pre-authorisation stage being appointed as the PRAC rapporteur could be applied.
Predlagano je bilo, naj se za zdravila, ki že imajo dovoljenje za promet, in postopke, ki potekajo, uporabi sistem, po katerem se za poročevalca PRAC imenuje poročevalca iz faze pred izdajo dovoljenja za promet.
[EMA/MB/955795/2012] The Management Board noted the document outlining the high-level budgetary requirements for 'Project 2014' (the move of the Agency to its new premises).
(EMA/MB/955795/2012) Upravni odbor se je seznanil z dokumentom o velikih proračunskih zahtevah za projekt za leto 2014 (selitev agencije v nove prostore).
• A discussion on the concept of public hearing and transparency.
• razpravo o konceptu javne obravnave in preglednosti,
• The implementing measures for the falsified medicines legislation (public consultations on unique identifier finishes 27 April 2012, on GMP for active substances from non-EU countries finishes 23
• ukrepi za izvajanje zakonodaje o ponarejenih zdravilih (javno posvetovanje o posebnem identifikatorju bo končano 27. aprila 2012, o dobri proizvodni praksi za zdravilne učinkovine iz držav, ki niso članice EU bo končano 23. marca 2012, o načelih in smernicah dobre proizvodne prakse za zdravilne učinkovine pa bo končano 20. aprila 2012);
This would increase the overall headcount by 14 FTEs.
To bi povečalo število zaposlenih za 14 ekvivalentov polne zaposlitve.
The discussion of the Board focused on the possible divergence of opinions between the PRAC and the CHMP/CMD(h).
Razprava upravnega odbora se je osredotočila na morebitna razhajanja mnenj odbora PRAC in odbora CHMP/skupine CMD(h).
The Board was informed that, to date, the Agency has introduced a revised policy on managing conflicts of interests of experts, adopted rules on managing conflicts of interests of staff, discussed the Management Board policy and presented it for adoption at this meeting, drafted the breach of trust procedure, is introducing ex post controls, has published risk ratings for committee members, and has
strokovnjakov, sprejela pravila o obvladovanju navzkrižij interesov osebja, razpravljala o politiki upravnega odbora in jo predložila v sprejetje na tej seji, pripravila osnutek postopka pri zlorabi zaupanja, uvaja naknadne kontrole ter je objavila ocene tveganj za člane odborov in strokovne profile direktorjev agencije ter članov odborov in upravnega odbora.
The Agency will draft a reflection paper based on the guidance provided today, and will seek written comments from the Board.
Agencija bo na podlagi tokrat sprejetih smernic pripravila osnutek študije in upravni odbor zaprosila za pisne pripombe.
It was also argued that the knowledge obtained about a product in the pre-authorisation stage is important for PRAC rapporteurship.
Nekateri so še trdili, da je znanje, pridobljeno o zdravilu v fazi pred izdajo dovoljenja za promet, pomembno tudi za poročanje odbora PRAC.
[EMA/MB/121516/2012] The Board adopted the Agency's preliminary draft budget and the draft establishment plan for 2013.
(EMA/MB/121516/2012) Upravni odbor je sprejel predhodni predlog proračuna in osnutek kadrovskega načrta agencije za leto 2013.
[EMA/MB/945561/2011] The Management Board adopted the Agency's preliminary draft work programme 2013.
(EMA/MB/945561/2011) Upravni odbor je sprejel predhodni osnutek delovnega programa agencije za leto 2013.
There are a number of precursors to adaptive licensing - such as conditional marketing authorisation, new pharmacovigilance legislation, risk-management plans, periodic safety update reports, etc.
Udeleženci so med razpravo ugotovili, da koncept kot tak na regulativnem področju ni popolnoma nov. Prilagodljivo izdajanje dovoljenj ima več predhodnih korakov, kot so pogojno izdajanje dovoljenj, nova zakonodaja o farmakovigilanci, načrti za obvladovanje tveganj, redno posodobljena poročila o varnosti zdravila itd.
• Consultation no. 15/2011 on the appointment of Esther Werner as CVMP alternate, proposed by Germany, ended, with observations from Members raised in respect of the candidate's expertise, on 3 January 2012.
• Posvetovanje št. 15/2011 o imenovanju Esther Werner za namestnico v odboru CVMP na predlog Nemčije, končano, člani so 3. januarja 2012 podali pripombe v zvezi s strokovnim znanjem kandidatke.
• Consultation no. 03/2012 on the appointment of Martti Nevalainen as CVMP member, proposed by Finland ended on 2 February 2012 with Members' observations, raised in respect of the candidate's level of conflict of interests and supported by the CVMP Chair, sent to the nominating authority on 13 February 2012.
• Posvetovanje št. 03/2012 o imenovanju Marttija Nevalainena za člana v odboru CVMP na predlog Finske, končano 2. februarja 2012 s pripombami članov v zvezi s kandidatovim navzkrižjem interesov, te je podprl tudi predsednik odbora CVMP in so bile 13. februarja 2012 poslane organu za imenovanja.
• [EMA/177625/2012 Rev.1] Minutes from the Management Board Telematics Committee meeting held on 14 February 2012.
• (EMA/177625/2012 Rev. 1) Zapisnik seje odbora za telematiko pri upravnem odboru z dne 14. februarja 2012.
A discussion on the concept of public hearing and transparency
1. zasedanje: razprava o konceptu javne obravnave in preglednosti
[EMA/154320/2012] The Management Board endorsed the breach of trust procedure on conflicts of interests for scientific-committee members and experts.
(EMA/154320/2012) Upravni odbor je potrdil postopek pri zlorabi zaupanja v zvezi z navzkrižjem interesov za člane znanstvenih odborov in strokovnjake.
The nominating authority confirmed the withdrawal of the nomination in a letter addressed to the MB Chair, received on 24 February 2012.
Ta je v dopisu predsedniku upravnega odbora, prejetem 24. februarja 2012, potrdil umik imenovanja.
• Consultation no. 02/2012 on the appointment of Outi Maki-Ikola as CHMP member, proposed by Finland, ended on 26 January 2012.
• Posvetovanje št. 02/2012 o imenovanju Outi Maki-Ikola za članico v odboru CHMP na predlog Finske, končano 26. januarja 2012.
The mandate of the nominee commenced on 9 December 2011.
Kandidatka je mandat nastopila 9. decembra 2011.
• Update on the implementation of the pharmacovigilance legislation.
• najnovejše podatke o izvajanju zakonodaje o farmakovigilanci,
The mandate of the nominee commenced on 4 January 2012.
Kandidatka je mandat nastopila 4. januarja 2012.
The mandate of the nominee commenced on 27 January 2012.
Kandidatka je mandat nastopila 27. januarja 2012.
• Publication of agendas and minutes.
• objavo dnevnih redov in zapisnikov,
• The implementing measures of the pharmacovigilance legislation (planned adoption in Q2 2012).
• ukrepi za izvajanje zakonodaje o farmakovigilanci (načrtovano sprejetje v drugem četrtletju leta
b.) Preliminary draft budget and establishment plan 2013
b.) Predhodni predlog proračuna in kadrovski načrt za leto 2013
[EMA/513078/2010] The Management Board endorsed the amendments to the revised conflicts of interests policy for Committee members and experts.
(EMA/513078/2010) Upravni odbor je potrdil spremembe spremenjene politike o navzkrižju interesov za člane odborov in strokovnjake.
Some outstanding work will be finalised by mid
Nekaj nedokončanih nalog bo izvedenih do sredine maja 2012.
[EMA/154547/2012] The Board noted the analysis on the implementation of the revised conflicts of interests policy for Committee members and experts.
(EMA/154547/2012) Upravni odbor se je seznanil z analizo izvajanja spremenjene politike o navzkrižju interesov za člane odborov in strokovnjake.
A gap of one week between PRAC and CHMP/CMD(h) meetings was proposed.
Predlagan je bil enotedenski premor med sejami odbora PRAC in odbora CHMP/skupine CMD(h).
The meeting also noted the proposal about the timing between PRAC and CHMP/CMD(h) meetings.
Udeleženci seje so se seznanili še s predlogom časovne uskladitve sej odbora PRAC in odbora CHMP/skupine CMD(h).
• Consultation no. 01/2012 on the appointment of Ingunn Hagen Westgaard as CHMP alternate, proposed by Norway, ended on 26 January 2012.
• Posvetovanje št. 01/2012 o imenovanju Ingunn Hagen Westgaard za namestnico v odboru CHMP na predlog Norveške, končano 26. januarja 2012.
• Consultation no. 13/2011 on the appointment of Merete Blixenkrone-Moller as CVMP alternate, proposed by Denmark, ended on 8 December 2011.
• Posvetovanje št. 13/2011 o imenovanju Merete Blixenkrone-Moller za namestnico v odboru CVMP na predlog Danske, končano 8. decembra 2011.
• Consultation no. 14/2011 on the appointment of Ugne Zymantaite as CVMP alternate, proposed by Lithuania, ended on 19 December 2011.
• Posvetovanje št. 14/2011 o imenovanju Ugne Zymantaite za namestnico v odboru CVMP na predlog Litve, končano 19. decembra 2011.
Representative of veterinarians' organisations Observers
Predstavnik veterinarskih organizacij
Wednesday meeting, held on 21 March 2012
Seja, ki je potekala v sredo, 21. marca 2012
EMA/MB/221361/2012 Adopted Management Board
EMA/518119/2012 sprejet upravni odbor
Thursday meeting, held on 22 March 2012
Seja, ki je potekala v četrtek, 22. marca 2012
Minutes from the 74th meeting, held on 15 December
Zapisnik 74. seje, ki je potekala 15. decembra 2011
The mandate of the nominee commenced on 20 December
Kandidatka je mandat nastopila 20. decembra 2011.
800 mg/150 mg Film-coated tablet Oral use
800 mg/150 mg filmsko obložena tableta peroralna uporaba plastenka (HDPE)
MA (EU) number (Invented) name
Številka postopka EMA (Izmišljeno) ime Jakost
Bottle (HDPE) 30 tablets
30 tablet
This applies to the following conditions:
To velja za naslednje bolezni:
Duration of Use
Trajanje uporabe
• if you are using another hormonal contraceptive
• če uporabljate drug hormonski kontraceptiv
Venous thromboembolism can be fatal in 1-2% of cases.
Venska trombembolija je lahko v 1 - 2 % primerov smrtna.